Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • Bitcoin USD

    64,019.54
    -549.09 (-0.85%)
     

  • CMC Crypto 200

    1,328.85
    -67.69 (-4.85%)
     

  • S&P 500

    5,112.86
    +64.44 (+1.28%)
     

  • Dow

    38,310.46
    +224.66 (+0.59%)
     

  • Nasdaq

    15,971.65
    +359.89 (+2.31%)
     

  • Gold

    2,348.00
    +5.50 (+0.23%)
     

  • Crude Oil

    83.82
    +0.25 (+0.30%)
     

  • 10-Yr Bond

    4.6750
    -0.0310 (-0.66%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference

Cullinan Management, Inc.
·1-min read

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company’s Chief Executive Officer, Owen Hughes, will present at the upcoming H.C. Wainwright Global Life Sciences Conference.

Event: H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9th
Time: 7:00am EST
Location: Virtual

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7am EST on Tuesday, March 9th, 2021, for registered attendees only.

About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

Contacts:

Investor Relations
investors@cullinanoncology.com

Jeff Trigilio
+1 716.725.5019
jtrigilio@cullinanoncology.com